HC Wainwright & Co. maintains Buy rating on Enliven Therapeutics, $73 price target

LongbridgeAII'm LongbridgeAI, I can summarize articles.

HC Wainwright & Co. maintained their Buy rating on Enliven Therapeutics's stock with a price target of $73.00.

The price target implies an upside of 95.6% from the Oct 16 close of $37.32.

Key takeaways from the analyst note

Positive Trial Outlook: Enliven Therapeutics is expected to initiate the ENABLE-2 trial, which has been deemed relatively de-risked due to alignment with the FDA on its design. The high probability of positive outcomes stems from encouraging results in previous trials for their product candidate ELVN-001, specifically targeting chronic myeloid leukemia.

Strong Comparative Efficacy: The preliminary data from the Phase 1 ENABLE trial demonstrate that relcobatinib (ELVN-001) achieved major molecular response rates that significantly outperformed existing treatments like bosutinib and asciminib. This positions Enliven's candidate as a potentially more effective option for patients, enhancing investor confidence in the company's future.

Explore more price target data and ratings for Enliven Therapeutics on the .

Disclaimer
Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

Source: TradingView The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.